Literature DB >> 24298343

Clinical outcome of 50 progressive multiple sclerosis patients treated with cellular therapy in iraq.

Abdul Majeed A Hammadi1, Andolina Marino, Saad Farhan.   

Abstract

BACKGROUND AND OBJECTIVES: Multiple Sclerosis is a disease characterized by multifocal areas of demyelination in the brain and spinal cord, with associated inflammatory cell infiltrates, reactive gliosis, and axonal degeneration. It typically presents in young adults with episodic neurologic dysfunction, our aim is to find new simple method to treat multiple sclerosis by hematopoietic stem cells derived from peripheral blood. METHODS AND
RESULTS: 50 patients suffering from multiple sclerosis worsening despite pharmacological treatment were treated by means of several intrathecal injections of peripheral blood cells harvested by aphaeresis after G-CSF(granulocyte colony stimulating factor) treatment. 24 patients (48% ) had a reduction of EDSS score. 8 patients had a relapse, but it was milder than usual and more easily controlled by cortisone.
CONCLUSIONS: Since mesenchymal cells increase in the peripheral blood after G-CSF stimulation, a peripheral blood harvest seems easier and cheaper than mesenchymal cells cultivation prior to the injection. It seems a reasonable treatment for progressive multiple sclerosis.

Entities:  

Keywords:  Cellular therapy; Mesenchymal cells; Multiple sclerosis

Year:  2011        PMID: 24298343      PMCID: PMC3840965          DOI: 10.15283/ijsc.2011.4.2.113

Source DB:  PubMed          Journal:  Int J Stem Cells        ISSN: 2005-3606            Impact factor:   2.500


  8 in total

1.  Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.

Authors:  Bassem Yamout; Roula Hourani; Haytham Salti; Wissam Barada; Taghrid El-Hajj; Aghiad Al-Kutoubi; Aline Herlopian; Elizabeth Kfoury Baz; Rami Mahfouz; Rima Khalil-Hamdan; Nabeela M A Kreidieh; Marwan El-Sabban; Ali Bazarbachi
Journal:  J Neuroimmunol       Date:  2010-08-21       Impact factor: 3.478

2.  Transplantation of human marrow stromal cells and mono-nuclear bone marrow cells into the injured spinal cord: a comparative study.

Authors:  Amer F Samdani; Courtney Paul; Randal R Betz; Itzhak Fischer; Birgit Neuhuber
Journal:  Spine (Phila Pa 1976)       Date:  2009-11-15       Impact factor: 3.468

3.  Granulocyte-colony stimulating factor-mobilized mesenchymal stem cells: A new resource for rapid engraftment in hematopoietic stem cell transplantation.

Authors:  Cheng Zhang; Xi Zhang; Xing-Hua Chen
Journal:  Med Hypotheses       Date:  2010-11-02       Impact factor: 1.538

4.  Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.

Authors:  R Saccardi; T Kozak; C Bocelli-Tyndall; A Fassas; A Kazis; E Havrdova; E Carreras; A Saiz; B Löwenberg; P A W te Boekhorst; F Gualandio; H Openshaw; G Longo; F Pagliai; L Massacesi; E Deconink; J Ouyang; F J Z Nagore; J Besalduch; I A Lisukov; A Bonini; E Merelli; S Slavino; A Gratwohl; J Passweg; A Tyndall; A J Steck; M Andolina; M Capobianco; J L D Martin; A Lugaresi; G Meucci; R A Sáez; R E Clark; M N Fernandez; L Fouillard; B Herstenstein; V Koza; E Cocco; H Baurmann; G L Mancardi
Journal:  Mult Scler       Date:  2006-12       Impact factor: 6.312

5.  Urokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells.

Authors:  Krishna C Vallabhaneni; Sergey Tkachuk; Yulia Kiyan; Nelli Shushakova; Hermann Haller; Inna Dumler; Gabriele Eden
Journal:  Cardiovasc Res       Date:  2010-11-18       Impact factor: 10.787

6.  Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NFkappaB-mediated increase in interleukin-6 production.

Authors:  Peter A Walker; Matthew T Harting; Fernando Jimenez; Shinil K Shah; Shibani Pati; Pramod K Dash; Charles S Cox
Journal:  Stem Cells Dev       Date:  2010-06       Impact factor: 3.272

7.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

8.  Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy.

Authors:  Phil Hyu Lee; Hyun Jung Park
Journal:  J Clin Neurol       Date:  2009-03-31       Impact factor: 3.077

  8 in total
  4 in total

1.  Clinical response of 277 patients with spinal cord injury to stem cell therapy in iraq.

Authors:  Abdulmajeed Alwan Hammadi; Andolina Marino; Saad Farhan
Journal:  Int J Stem Cells       Date:  2012-05       Impact factor: 2.500

2.  Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases.

Authors:  Kuang Pan; Lingna Deng; Peiying Chen; Qingxia Peng; Jingrui Pan; Yanfeng Wu; Yidong Wang
Journal:  Stem Cells Int       Date:  2019-07-25       Impact factor: 5.443

3.  Intrathecal Autologous Bone Marrow-Derived Hematopoietic Stem Cell Therapy in Neurological Diseases.

Authors:  M Zakerinia; A Kamgarpour; H Nemati; H R Zare; M Ghasemfar; A R Rezvani; M Karimi; H Nourani Khojasteh; M Dehghani; R Vojdani; S Haghighat; N Namdari; J Rekabpoor; M Tavazo; S Amirghofran; Z Amirghofran; G A Yosefipour; M Ramzi
Journal:  Int J Organ Transplant Med       Date:  2018-11-01

Review 4.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.